The global L-Alanyl-L-Glutamine market is estimated to reach USD 300 to 500 million in 2025, with a projected compound annual growth rate (CAGR) of 5% to 6% from 2025 to 2030. This growth is propelled ...
Several studies have evaluated the benefit of oral or parenteral glutamine supplementation in cancer patients receiving chemo/radiotherapy, 1,2,3,4 including high-dose therapy (HDT) and stem cell ...
Alanyl-Glutamine containing peritoneal dialysis fluid receives orphan drug designation in patients suffering from chronic kidney failure. Reduces the risk of causing a damage to the abdominal tissues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results